Bandingkan Harga & Kinerja Pelat Timah Nusantara Tbk. (NIKL) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Pelat Timah Nusantara Tbk. dan Organon Pharma Indonesia Tbk.: Pelat Timah Nusantara Tbk. diperdagangkan di Rp224 (kapitalisasi pasar 595,51 M, volume 24 jam 9,73 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Pelat Timah Nusantara Tbk. jauh lebih besar — sekitar 5,7× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| NIKL | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 595,51 M | 104,4 M |
Volume | 9,73 jt | — |
Lot | 97,35 rb | — |
Perputaran | 2,21 M | — |
Harga Rata-rata | 227,38 | — |
Nilai Transaksi | 2,21 M | — |
Harga Ekuilibrium Indikatif | 224 | — |
Volume Ekuilibrium Indikatif | 2,27 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Pelat Timah Nusantara Tbk.
PT Pelat Timah Nusantara Tbk (PT Latinusa) was the first company in Indonesia that produces high-quality tinplate with international standards. PT Latinusa was founded on August 19, 1982 under the Company Act No.45, drawn up before Imas Fatimah, SH, and the current majority shareholder is the Japanese consortium consisting of Nippon Steel Corporation, Mitsui Co.. Ltd.., Nippon Steel Trading Co.., And Metal One. Nippon Steel Corporation is also the provider of our main raw material, Tin Mill Black Plate (TMBP), so the availability of raw materials is always guaranteed.
Selengkapnya di halaman NIKL →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
